Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreat

Immunovia (NASDAQ: IMMNOV) (STO: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces today that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test.

As announced in November 2023, Immunovia successfully finalized a discovery study that evaluated nearly 3,000 proteins to identify 15 promising protein biomarkers for its next-generation test to detect early-stage pancreatic cancer.

As the next milestone in developing its next-generation test Immunovia, in collaboration with the company’s research and development partner Proteomedix (an Onconetix company), has developed accurate and reliable assays to measure the most promising proteins identified in the discovery study to move forward to a model-development study.

The newly developed assays leverage commercial reagents and an automated, high-throughput ELISA testing platform. By moving from the proprietary IMMray platform used for Immunovia’s prior test, IMMray PanCan-d, to the widely used commercial ELISA platform, Immunovia expects to substantially reduce lead-time in production as well as cost of goods sold for its next generation test.